Family Offices Fuel Biotech Funding Boom

Investment firms backed by ultra-wealthy families are playing a crucial role in revitalizing venture capital funding for biotechnology. In August, family offices executed 52 direct investments in private companies, with biotech startups securing about 20% of these transactions.

Stanley Druckenmiller's Duquesne Family Office, recognized as a highly active entity in the U.S., has invested in at least four pharmaceutical or life sciences companies this year. Recently, Duquesne participated in a $90 million Series C funding round for Epicrispr Biotechnologies, a startup focused on a novel gene therapy for facioscapulohumeral muscular dystrophy.

Druckenmiller noted in January that Duquesne had made substantial biotech investments, driven by the transformative potential of artificial intelligence in areas such as drug discovery and diagnostics. This perspective aligns with the broader trend of AI fueling venture funding for biopharma startups with existing drug candidates in testing phases.

The family office of Jeff Bezos also joined a $188 million Series E investment in LifeMine Therapeutics, a company utilizing AI to develop new drugs by analyzing fungal genomes. Bill Gates' venture capital firm, Gates Frontier, was also part of this significant funding round.

Collectively, U.S. and European biopharma startups raised $12.6 billion in the first half of 2026, marking a five-year high. However, investors are exhibiting a trend of making fewer, yet more substantial, investments, with a clear preference for companies possessing drugs already undergoing testing.